Carcinoid syndrome diarrhea is caused by a carcinoid tumor that secretes serotonin and other chemicals into patients’ bloodstream, which cause diarrhea in 80% incidences. Complications of uncontrolled diarrhea include malnutrition, weight loss, dehydration, and electrolyte imbalance. Signs and symptoms of carcinoid syndrome include flushing of the face, asthma caused due to vasoconstriction, debilitating diarrhea, intestinal bleeding, fast heartbeat, shortness of breath, sweating, and unexplained weight gain.
Carcinoid tumors, also known as metastatic neuroendocrine tumors, are rare and slow developing tumors that predominantly occur in the gastrointestinal tract or lungs. According to the U.S. Food and Drug Administration (FDA), less than 10% of the population with carcinoid tumors develops symptoms of carcinoid syndrome.
The increasing prevalence of carcinoid syndrome diarrhea is the leading factor that drives market growth. According to the National Organization for Rare Disorders (NORD), in the U.S., more than 27 incidences of carcinoid syndrome diarrhoea per million are detected every year. The prevalence rate is the same in male and female and gastrointestinal cases mostly occur in the middle-aged population.
On the other hand, low awareness hinders market growth in developing regions such as Asia Pacific and Latin America.
The carcinoid syndrome diarrhea treatment market is expected to grow at a healthy CAGR of 13.2% during the forecast period, 2019–2026.
The global carcinoid syndrome diarrhea treatment market has been segmented by treatment type, distribution channel, end user, and region.
On the basis of treatment type, the market has been segmented into chemotherapy, somatostatin analog (SSA) therapy, and oral therapy. The somatostatin analog (SSA) therapy segment is projected to hold a prominent market share, owing to the high effectiveness of this therapy in carcinoid syndrome diarrhea treatment.
On the basis of distribution channel, the carcinoid syndrome diarrhea treatment market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to account for a noteworthy market share, owing to the growing number of hospital pharmacies around the globe.
Based on end user, the carcinoid syndrome diarrhea treatment market has been segmented into hospitals, clinics, and cancer institutes and treatment centers. The cancer institutes segment is projected to gain a substantial market share, owing to the growing demand for specialized medical treatment.
By region, the global carcinoid syndrome diarrhea treatment market has been segmented into North America, Europe, Asia Pacific, and Latin America and the Middle East & Africa (LAMEA).
North America is expected to dominate the carcinoid syndrome diarrhea treatment market during the forecast period, owing to the increasing prevalence of carcinoid syndrome diarrhea and high healthcare expenditure in the region. The U.S. FDA is approving new orphan drugs for carcinoid syndrome diarrhea, which is expected to further support market growth in the region.
Europe is pegged to be the second largest carcinoid syndrome diarrhea treatment market globally, followed by Asia Pacific. Europe’s growing geriatric population, coupled with increasing investments in healthcare, is also expected to contribute to the growing demand for carcinoid syndrome diarrhea treatment. As of 2017, the geriatric population in Europe accounted for 19.4% of the region’s total population (Eurostat).
Asia Pacific is expected to observe significant growth in the global carcinoid syndrome diarrhea treatment market, owing to increasing prevalence of respiratory diseases such as asthma, COPD, and rhinosinusitis, and high number of smokers in the region. According to the World Bank Group, smoking prevalence in India’s male population was 20.6% in 2016.
The LAMEA carcinoid syndrome diarrhea treatment market is expected to witness sluggish growth during the forecast period, owing to the poor healthcare infrastructure in Africa. However, growing urbanization, improving healthcare infrastructure, and high disposable income in the Middle Eastern countries such as UAE, Saudi Arabia, and Kuwait, among others are projected to drive market growth to some extent.
Some of the key players in the global carcinoid syndrome diarrhea treatment market include Lexicon Pharmaceuticals, Inc., Novartis International AG (Sandoz) (Switzerland), Pharmascience Inc. (Canada), Omega Laboratories Ltd. (Canada), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (U.S.), Ipsen Biopharmaceuticals, Inc. (U.S.), Sirtex Medical Limited (Australia), BTG International Ltd. (U.K.), and Wockhardt Ltd.